Side-by-side · Research reference

AdamaxvsMazdutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BPhase 3HUMAN-REVIEWED19/62 cited

Adamax

ACTH(4-10) Analogue · Russian Nootropic

1.4×BDNF protein ↑Dolotov 2006

3×BDNF mRNA (exon III)Dolotov 2006

1.6×trkB phosphorylationDolotov 2006

Intranasal · Research Use Only

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

01Mechanism of Action

Parameter

Adamax

Mazdutide

Primary target

Melanocortin receptors (MC-Rs) in hippocampus and cortex

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Pathway

ACTH(4-10) fragment → MC-R binding → BDNF/trkB upregulation → neurotrophic signaling

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

Downstream effect

Increased hippocampal BDNF expression, trkB tyrosine phosphorylation, enhanced conditioned avoidance learning, circadian rhythm normalizationDolotov 2006 Arushanian 2008

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Feedback intact?

Non-endocrine — devoid of adrenal axis effectsvan 1978

Yes — physiological receptor-mediated signaling preserved

Origin

ACTH(4-10) fragment with modified amino acid sequence at positions 8, 9, 10Teter 2001

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Antibody development

—

02Dosage Protocols

Parameter

Adamax

Mazdutide

Animal dose (rat)

50 mcg/kg body weightDolotov 2006

Single intranasal application; produced maximal BDNF response.

—

Route

IntranasalDolotov 2006 Smolnik 2000

SubcutaneousJi 2026

Frequency

Single-dose or chronic administration protocols

Chronic dosing normalized circadian rhythms; single-dose produced acute BDNF elevation.

Once weeklyJi 2026 Luo 2026

Human dose (exploratory)

Not established — limited human data

ACTH(4-10) and analogs dosed 30–60 mcg intranasally in early human studies.

—

Evidence basis

Animal (rodent, rabbit) studies; minimal human RCT data

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Timing

Variable — chronic administration for circadian effects

—

Phase 2 studied dose

—

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

Dose escalation

—

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

Duration (trials)

—

24–48 weeks

Population

—

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

Phase 3 comparator

—

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

03Metabolic / Fat Loss Evidence

Parameter

Adamax

Mazdutide

Percentage body weight loss

—

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

Absolute weight loss

—

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

Responder rate (≥10% loss)

—

Not explicitly reported in available abstracts

Mechanism

—

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

BMI reduction

—

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

Visceral fat

—

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

Glycemic improvement

—

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

Comparator efficacy

—

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

Key publications

—

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

04Side Effects & Safety

Parameter

Adamax

Mazdutide

Cardiovascular effects

ACTH(4-10) fragments may have pressor and cardioaccelerator actions at high dosesGruber 1984

Effects attenuated by α/β-receptor antagonists; observed at 30–1000 nmol/kg IV in rats.

Increased heart rate (glucagon effect, transient)

Natriuretic effect

ACTH(4-10) exhibited natriuretic activity at lower doses (7 nmol/kg)Gruber 1984

—

Behavioral suppression

Suppression of aggression, reduced orientation-cognition reactions in rabbitsTeter 2001

May reflect anxiolytic or stress-dampening profile.

—

Long-term safety

Unknown — chronic human safety data lacking

—

Gastrointestinal symptoms

—

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

Injection site reactions

—

Erythema, pruritus, local discomfort

Hypoglycemia

—

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

Pancreatitis risk

—

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

Thyroid C-cell tumors

—

Black box warning for GLP-1 class (rodent data); human relevance unclear

Gallbladder disease

—

Cholelithiasis, cholecystitis (rapid weight loss effect)

Tolerability

—

Generally well-tolerated; GI effects diminish with dose titration

Absolute Contraindications

Adamax

·Pregnancy and lactation (precautionary; no data)
·Active cardiovascular instability (due to potential pressor effects)

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Relative Contraindications

Adamax

·Hypertension (monitor BP if using higher doses)
·Renal impairment (natriuretic effects may alter electrolyte balance)

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

05Administration Protocol

Parameter

Adamax

Mazdutide

1. Reconstitution (if lyophilised)

Add sterile water or bacteriostatic water to lyophilised vial per manufacturer guidance. Roll gently — do not shake. Ensure clarity before use.

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

2. Route

Intranasal administration is the primary route in animal and exploratory human studies. Delivered via nasal spray or dropper to ensure mucosal absorption.Dolotov 2006 Smolnik 2000

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

3. Timing

Variable. Single-dose protocols for acute cognitive tasks; chronic daily dosing for circadian rhythm normalization and sustained neuroprotection.

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within manufacturer-specified timeframe.

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

5. Needle technique

—

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

06Stack Synergy

Adamax

+ Semax

Moderate

View Semax →

Both Adamax and Semax are ACTH(4-10)-derived nootropics acting via melanocortin receptors and BDNF upregulation. Adamax has distinct amino acid modifications at positions 8-10, potentially offering complementary receptor binding profiles or metabolic stability. Stacking may amplify neurotrophic signaling and cognitive enhancement, though direct synergy studies are absent. Theoretical multi-pathway benefit.

Adamax: Research dose intranasal
Semax: 300–600 mcg intranasal
Frequency: Once daily, morning or pre-cognitive task
Primary benefit: Enhanced BDNF upregulation, cognitive performance, neuroprotection

Mazdutide

— no documented stacks